SLLK, Control Peptide for TSP1 Inhibitor (TFA)

SLLK, Control Peptide for TSP1 Inhibitor (TFA) is a control peptide for LSKL, which is a Thrombospondin (TSP-1) inhibitor.

Product Specifications

UNSPSC

12352209

Target

TGF-β Receptor

Type

Peptides

Related Pathways

TGF-beta/Smad

Applications

Cancer-programmed cell death

Field of Research

Cancer

Assay Protocol

https://www.medchemexpress.com/SLLK,_Control_Peptide_for_TSP1_Inhibitor_TFA_.html

Purity

99.83

Solubility

H2O : ≥ 100 mg/mL

Smiles

O=C(N[C@@H](CC(C)C)C(N[C@@H](CC(C)C)C(N[C@@H](CCCCN)C(N)=O)=O)=O)[C@H](CO)N.OC(C(F)(F)F)=O

Molecular Formula

C23H43F3N6O7

Molecular Weight

572.62

References & Citations

[1]Lu A, et al. Blockade of TSP1-dependent TGF-β activity reduces renal injury and proteinuria in a murine model of diabetic nephropathy. Am J Pathol. 2011 Jun;178 (6) :2573-86.|[2]Krishna SM, et al. A peptide antagonist of thrombospondin-1 promotes abdominal aortic aneurysm progression in the angiotensin II-infused apolipoprotein-E-deficient mouse. Arterioscler Thromb Vasc Biol. 2015 Feb;35 (2) :389-98.